You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 127 No. 1, January 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Trial
 This Article
 •Full text
 •PDF
 •eTables
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Pediatric Ophthalmology
 •Ophthalmological Disorders, Other
 •Pediatrics
 •Pediatrics, Other
 •Randomized Controlled Trial
 •Prognosis/ Outcomes
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Pharmacological Plus Optical Penalization Treatment for Amblyopia

Results of a Randomized Trial

Pediatric Eye Disease Investigator Group*

Arch Ophthalmol. 2009;127(1):22-30.

Objective  To compare weekend atropine sulfate use augmented by a plano lens for the sound eye with weekend atropine use alone for moderate amblyopia in children aged 3 years to younger than 7 years.

Methods  In a multicenter clinical trial, 180 children with moderate amblyopia (visual acuities of 20/40-20/100) were randomized to weekend atropine use augmented by a plano lens or weekend atropine use alone.

Main Outcome Measure  Masked assessment of amblyopic eye visual acuity using the Amblyopia Treatment Study HOTV testing protocol at 18 weeks.

Results  At 18 weeks, amblyopic eye improvement averaged 2.8 lines in the group that received atropine plus a plano lens and 2.4 lines in the group that received atropine alone (mean difference between groups adjusted for baseline acuity, 0.3 line; 95% confidence interval, –0.2 to 0.8 line). Amblyopic eye visual acuity was 20/25 or better in 24 patients (29%) in the group that received atropine only and 35 patients (40%) in the group that received atropine plus a plano lens (P = .03). More patients in the group that received atropine plus a plano lens had reduced sound eye visual acuity at 18 weeks; however, there were no cases of persistent reverse amblyopia.

Conclusions  As an initial treatment for moderate amblyopia, the augmentation of weekend atropine use with a plano lens does not substantially improve amblyopic eye visual acuity when compared with weekend atropine use alone.

Application to Clinical Practice  Treatment of children with unilateral amblyopia.

Trial Registration  clinicaltrials.gov Identifier: NCT00315302



*Authors/Writing Committee: The following members of the Pediatric Eye Disease Investigator Group take authorship responsibility for the study results: Susan A. Cotter, OD, MS; David R. Weakley Jr , MD; Samara F. Strauber, MS; Roy W. Beck, MD, PhD; Eileen E. Birch, PhD; Sean Donahue, MD, PhD; Jonathan M. Holmes, BM, BCh; Darren L. Hoover, MD; Pamela A. Huston; B. Michele Melia, ScM; Michael X. Repka, MD; and David T. Wheeler, MD.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.